[go: up one dir, main page]

NI200900031A - Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos. - Google Patents

Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos.

Info

Publication number
NI200900031A
NI200900031A NI200900031A NI200900031A NI200900031A NI 200900031 A NI200900031 A NI 200900031A NI 200900031 A NI200900031 A NI 200900031A NI 200900031 A NI200900031 A NI 200900031A NI 200900031 A NI200900031 A NI 200900031A
Authority
NI
Nicaragua
Prior art keywords
compositions
methylaminomethyl
methods
isoindol
compounds
Prior art date
Application number
NI200900031A
Other languages
English (en)
Inventor
W Muller George
S C Chen Roger
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of NI200900031A publication Critical patent/NI200900031A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

La invención se refiere a compuestos de N-metilaminometil-isoindolina, y sales farmacéuticamente aceptables, solvatos, estereoisómeros, y profármacos de los mismos. Se describen métodos de uso, y composiciones farmacéuticas de estos compuestos.
NI200900031A 2006-09-15 2009-03-13 Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos. NI200900031A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84522706P 2006-09-15 2006-09-15

Publications (1)

Publication Number Publication Date
NI200900031A true NI200900031A (es) 2010-02-01

Family

ID=38983295

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900031A NI200900031A (es) 2006-09-15 2009-03-13 Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos.

Country Status (30)

Country Link
US (2) US8648096B2 (es)
EP (1) EP2076260B1 (es)
JP (1) JP5567339B2 (es)
KR (1) KR20090050107A (es)
CN (2) CN101534820A (es)
AR (1) AR062875A1 (es)
AT (1) ATE502634T1 (es)
CA (1) CA2663376C (es)
CL (1) CL2007002670A1 (es)
CO (1) CO6180446A2 (es)
CR (1) CR10696A (es)
CY (1) CY1112558T1 (es)
DE (1) DE602007013436D1 (es)
DK (1) DK2076260T3 (es)
ES (1) ES2361584T3 (es)
HR (1) HRP20110261T1 (es)
IL (1) IL197566A0 (es)
MX (1) MX2009002666A (es)
NI (1) NI200900031A (es)
NZ (1) NZ575689A (es)
PE (1) PE20080832A1 (es)
PL (1) PL2076260T3 (es)
PT (1) PT2076260E (es)
RS (1) RS51725B (es)
RU (1) RU2009114159A (es)
SI (1) SI2076260T1 (es)
TW (1) TW200819435A (es)
UA (1) UA95975C2 (es)
WO (1) WO2008033567A1 (es)
ZA (1) ZA200901852B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070057907A (ko) * 2004-09-03 2007-06-07 셀진 코포레이션 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린의제조 방법
DK2380887T3 (da) * 2005-06-30 2013-10-07 Celgene Corp Fremgangsmåder til fremstilling af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion-forbindelser
DK2076260T3 (da) * 2006-09-15 2011-06-27 Celgene Corp N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
NZ592425A (en) * 2008-10-29 2013-04-26 Celgene Corp Isoindoline compounds for use in the treatment of cancer
EA201100984A1 (ru) 2008-12-19 2012-01-30 Грэйсуэй Фармасьютикалс, Ллс Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения актинического кератоза
PL2453747T3 (pl) * 2009-07-13 2018-02-28 Medicis Pharmaceutical Corporation Preparaty imikwimodu o niższej mocy dawki i krótkie schematy dawkowania do leczenia brodawek narządów płciowych i okolic odbytu
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US11295846B2 (en) 2011-12-21 2022-04-05 Deka Products Limited Partnership System, method, and apparatus for infusing fluid
EP2943201B2 (en) 2013-01-14 2020-07-29 Deuterx, LLC 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153100A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
BR112015022785A2 (pt) 2013-03-14 2017-07-18 Epizyme Inc composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
WO2014178954A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014152833A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014153090A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives asprmt1 inhibitors and uses thereof
JP6389241B2 (ja) 2013-04-17 2018-09-12 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのＴＯＲキナーゼ阻害剤及びＩＭｉＤ化合物を含む組合せ療法
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
BR112017002403A2 (pt) 2014-08-07 2017-12-05 Calithera Biosciences Inc formas de cristais de inibidores de glutaminase
PL3214081T3 (pl) * 2014-10-30 2021-04-06 Kangpu Biopharmaceuticals, Ltd. Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017040376A1 (en) * 2015-08-31 2017-03-09 The University Of Toledo Potent phthalate inhibitors of aspartate n-acetyltransferase and selective aspartate pathway inhibitors
TWI728017B (zh) 2015-12-15 2021-05-21 瑞典商阿斯特捷利康公司 異吲哚化合物、包含其之醫藥組成物及其用途
US10759808B2 (en) * 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3532464A4 (en) 2016-10-28 2020-07-08 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
AU2017370694A1 (en) 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
CN110730780A (zh) 2017-06-14 2020-01-24 阿斯利康(瑞典)有限公司 用作ROR-γ调节剂的2，3-二氢异吲哚-1-甲酰胺
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3679028A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydroquinolinones
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADATION AND DEGRADATION AGENTS FOR TARGETED PROTEIN DEGRADATION
AU2019231689A1 (en) * 2018-03-06 2020-09-24 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
MX2020011183A (es) * 2018-04-23 2020-11-12 Celgene Corp Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
EA202192738A1 (ru) 2019-04-12 2022-03-17 С4 Терапьютикс, Инк. Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
CA3137916A1 (en) 2019-05-06 2020-11-12 Ichan School Of Medicine At Mount Sinai Heterobifunctional compounds as degraders of hpk1
EP4048279A1 (en) 2019-10-21 2022-08-31 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
CA3154956A1 (en) * 2019-10-21 2021-04-29 Lianfeng Huang Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
EP4048668A4 (en) * 2019-10-21 2024-03-13 Celgene Corporation Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CN110746400B (zh) * 2019-11-07 2021-12-17 郑州大学 一种靶向雄激素受体的荧光探针及其制备方法
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
CA3249074A1 (en) 2022-06-06 2023-12-14 C4 Therapeutics, Inc. BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
BR9908811A (pt) * 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
WO2004054977A1 (en) * 2002-12-13 2004-07-01 Cytopia Pty Ltd Nicotinamide-based kinase inhibitors
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
DK2380887T3 (da) * 2005-06-30 2013-10-07 Celgene Corp Fremgangsmåder til fremstilling af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion-forbindelser
DK2076260T3 (da) * 2006-09-15 2011-06-27 Celgene Corp N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse

Also Published As

Publication number Publication date
CL2007002670A1 (es) 2008-05-16
EP2076260B1 (en) 2011-03-23
WO2008033567A1 (en) 2008-03-20
PE20080832A1 (es) 2008-08-06
RU2009114159A (ru) 2010-10-20
EP2076260A1 (en) 2009-07-08
IL197566A0 (en) 2009-12-24
PT2076260E (pt) 2011-06-07
TW200819435A (en) 2008-05-01
DE602007013436D1 (de) 2011-05-05
MX2009002666A (es) 2009-04-09
NZ575689A (en) 2011-12-22
US20080214615A1 (en) 2008-09-04
KR20090050107A (ko) 2009-05-19
ES2361584T3 (es) 2011-06-20
ZA200901852B (en) 2010-06-30
RS51725B (sr) 2011-10-31
CA2663376C (en) 2015-01-06
PL2076260T3 (pl) 2011-08-31
AR062875A1 (es) 2008-12-10
CN101534820A (zh) 2009-09-16
JP5567339B2 (ja) 2014-08-06
CN103382197A (zh) 2013-11-06
CR10696A (es) 2009-05-13
DK2076260T3 (da) 2011-06-27
UA95975C2 (ru) 2011-09-26
US8648096B2 (en) 2014-02-11
US20140113935A1 (en) 2014-04-24
CA2663376A1 (en) 2008-03-20
HRP20110261T1 (hr) 2011-05-31
ATE502634T1 (de) 2011-04-15
JP2010503688A (ja) 2010-02-04
SI2076260T1 (sl) 2011-05-31
CY1112558T1 (el) 2016-02-10
CO6180446A2 (es) 2010-07-19

Similar Documents

Publication Publication Date Title
NI200900031A (es) Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos.
CR9772A (es) Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos
ECSP10010724A (es) Compuestos de isoindol 5-sustituidos
NI200900170A (es) Derivados de isoindolina 4' - o - sustituidos y composiciones que los comprenden y métodos para usar los mismos.
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
NI201200132A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos
CR10636A (es) Inhibidor de quinasa
CO6280399A2 (es) Peptidil nitrilos y uso de los mismos como inhibidores de peptidil peptidasa i
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CR9851A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
UY30141A1 (es) Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato
GT200900292A (es) "inhibidores de cinasa p70 s6"
UY30304A1 (es) Moduladores de mglur5 i
CU23779B7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
EA201171488A1 (ru) Lxr модуляторы
UY30308A1 (es) Moduladores de mglur5 v
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
NI200900052A (es) Heterocíclicos derivados de los inhibidores de metaloproteasa
ECSP077270A (es) Ácidos de tiazolo - naftilo
UY30307A1 (es) Moduladores de mglur5 vi
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
UY30306A1 (es) Moduladores de mglur5 iii